{"product_id":"phytotherapies-efficacy-safety-and-regulation-hardback-9781118268063","title":"Phytotherapies; Efficacy, Safety, and Regulation (Hardback) 9781118268063","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003ePhytotherapies\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003eEfficacy, Safety, and Regulation\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eIqbal Ramzan (Edited by), I Ramzan (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781118268063, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 23 June 2015\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e680 pages\u003cbr\u003e24.4 x 16.3 x 3.9 cm, 1.048 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eCovering fundamentals and new developments in phytotherapy, this book combines pharmaceutical sciences and chemistry with clinical issues.\u003cbr\u003e \u003cbr\u003e •    Helps readers better understand phytotherapy and learn the fundamentals of and how to analyze phytotherapeutic agents\u003cbr\u003e •    Discusses phytotherapy in modern medicine, chemoprevention of disease, and  alternatives to western medicines for specific diseases\u003cbr\u003e •    Chapters summarizes the uses and applications of phytomedicines, by type like Chinese, Greco-Arab, Indian, European, and Ayurvedic\u003cbr\u003e •    Includes international regulatory perspectives and discusses emerging regulations for various established and emerging markets\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eList of Contributors xvii\u003c\/p\u003e \u003cp\u003ePreface xxi\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Phytotherapies—Past, Present, and Future 1\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eIqbal Ramzan and George Q. Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Overview of Phytotherapy 1\u003c\/p\u003e \u003cp\u003e1.2 Preclinical Research on Phytotherapies 3\u003c\/p\u003e \u003cp\u003e1.3 Clinical Research on Phytotherapies 6\u003c\/p\u003e \u003cp\u003e1.4 Safety of Phytotherapies 8\u003c\/p\u003e \u003cp\u003e1.5 Profile of Research in Complementary Medicine 9\u003c\/p\u003e \u003cp\u003e1.6 Summary and Future Directions 12\u003c\/p\u003e \u003cp\u003eReferences 12\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Quality Control and Quality Assurance of Phytomedicines: Key Considerations, Methods, and Analytical Challenges 18\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eWai‐Ping Yau, Cheong Hian Goh, and Hwee‐Ling Koh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 18\u003c\/p\u003e \u003cp\u003e2.2 Key Considerations in QC\/QA of Phytomedicines 20\u003c\/p\u003e \u003cp\u003e2.3 Methods for QC\/QA of Phytomedicines 27\u003c\/p\u003e \u003cp\u003e2.4 Challenges 37\u003c\/p\u003e \u003cp\u003e2.5 Conclusions 40\u003c\/p\u003e \u003cp\u003eReferences 40\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Preclinical (\u003ci\u003eIn Vivo\u003c\/i\u003e) and Laboratory (\u003ci\u003eIn Vitro\u003c\/i\u003e) Evidence of Phytomedicine Efficacy 49\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMohi Iqbal Mohammed Abdul and Tom Hsun‐Wei Huang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction to Development of Drugs from Nature 49\u003c\/p\u003e \u003cp\u003e3.2 Use of \u003ci\u003eIn Vitro and in Vivo \u003c\/i\u003eModels in Herb Drug Research: Learning Thus Far 50\u003c\/p\u003e \u003cp\u003e3.3 Cardiovascular‐ and Stroke‐Related Diseases: \u003ci\u003eIn Vitro \u003c\/i\u003eand \u003ci\u003eIn Vivo \u003c\/i\u003eFocus 53\u003c\/p\u003e \u003cp\u003e3.4 Conclusions 60\u003c\/p\u003e \u003cp\u003eReferences 61\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Clinical Efficacy Trials with Natural Products and Herbal Medicines 65\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eChristina L. Nance\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 65\u003c\/p\u003e \u003cp\u003e4.2 Trials in Various Disease States 66\u003c\/p\u003e \u003cp\u003e4.3 Natural Product: Green Tea 73\u003c\/p\u003e \u003cp\u003e4.4 EGCG Clinical Trials 75\u003c\/p\u003e \u003cp\u003e4.5 Human Clinical Study: EGCG and HIV‐1 Infection 78\u003c\/p\u003e \u003cp\u003e4.6 Conclusion 80\u003c\/p\u003e \u003cp\u003eReferences 80\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Novel Formulations and Drug Delivery Systems for Phytotherapies 89\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eShengpeng Wang, Meiwan Chen, Qi (Tony) Zhou, and Hak‐Kim Chan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Limitations of Conventional Formulations for Herbal Medicines 89\u003c\/p\u003e \u003cp\u003e5.2 Crucial Issues of Developing Novel Delivery Systems for Herbal Medicines 91\u003c\/p\u003e \u003cp\u003e5.3 Novel Delivery Systems of Herbal Medicines 93\u003c\/p\u003e \u003cp\u003e5.4 Summary 96\u003c\/p\u003e \u003cp\u003eReferences 97\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Phytotherapies Used by Indigenous Populations 101\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eBradley S. Simpson and Susan J. Semple\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 101\u003c\/p\u003e \u003cp\u003e6.2 Phytotherapies of Indigenous Australians 103\u003c\/p\u003e \u003cp\u003e6.3 Challenges of a Changing Environment 114\u003c\/p\u003e \u003cp\u003e6.4 Conclusions 117\u003c\/p\u003e \u003cp\u003eReferences 118\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Phytotherapies from Traditional Chinese Medicine 122\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMichael Rieder\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Traditional Chinese Medicine 122\u003c\/p\u003e \u003cp\u003e7.2 Key Concepts in Traditional Chinese Medicine 124\u003c\/p\u003e \u003cp\u003e7.3 Herbal Medicine and Traditional Chinese Medicine 126\u003c\/p\u003e \u003cp\u003e7.4 Issues in the Development of Phytotherapy from Traditional Chinese Medicine 130\u003c\/p\u003e \u003cp\u003e7.5 Phytotherapies Developed from Traditional Chinese Medicine 131\u003c\/p\u003e \u003cp\u003e7.6 Huang Qin Tang and the Development of PHY906 134\u003c\/p\u003e \u003cp\u003e7.7 Ginseng 136\u003c\/p\u003e \u003cp\u003e7.8 Moving Forward 138\u003c\/p\u003e \u003cp\u003eReferences 138\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Integrating Traditional Greco‐Arab and Islamic Diet and Herbal Medicines in Research and Clinical Practice 142\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eBashar Saad\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 142\u003c\/p\u003e \u003cp\u003e8.2 Food Therapy in Greco‐Arab and Islamic Medicine 147\u003c\/p\u003e \u003cp\u003e8.3 Medicinal Plants 157\u003c\/p\u003e \u003cp\u003eReferences 177\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Evolution of Herbal Medicines in Europe and its Relationship with Modern Medicine 183\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eElizabeth M. Williamson and Kelvin Chan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Background 183\u003c\/p\u003e \u003cp\u003e9.2 Historical Perspective 184\u003c\/p\u003e \u003cp\u003e9.3 European Herbal Medicine: Relationship with Modern Medicine 194\u003c\/p\u003e \u003cp\u003e9.4 Summary 194\u003c\/p\u003e \u003cp\u003eReferences 196\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Chemical Classification and Chemistry of Phytotherapeutics Constituents 199\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePei H. Cui and Colin C. Duke\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 199\u003c\/p\u003e \u003cp\u003e10.2 Phytochemicals 201\u003c\/p\u003e \u003cp\u003e10.3 Other Phytochemicals 215\u003c\/p\u003e \u003cp\u003e10.4 Medicinal Effects Relating to Dietary Intake 217\u003c\/p\u003e \u003cp\u003e10.5 Natural Products as Leads for Drug Development 223\u003c\/p\u003e \u003cp\u003e10.6 Summary 230\u003c\/p\u003e \u003cp\u003eReferences 230\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Therapeutic Potential of Ginsenosides in Management of Atherosclerosis 236\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eXiao‐Jing Zhang, Huanxing Su, Yi-Tao Wang, and Jian-Bo Wan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 236\u003c\/p\u003e \u003cp\u003e11.2 Chemical Diversity of Ginsenosides and Distribution 238\u003c\/p\u003e \u003cp\u003e11.3 Anti‐Atherosclerotic Effects of Ginsenosides 240\u003c\/p\u003e \u003cp\u003e11.4 Underlying Mechanisms of Ginsenosides Against Atherosclerosis 244\u003c\/p\u003e \u003cp\u003e11.5 Conclusions and Future Perspectives 258\u003c\/p\u003e \u003cp\u003eAcknowledgments 258\u003c\/p\u003e \u003cp\u003eReferences 258\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Phytotherapy Pharmacophores for Major Cellular Drug Targets 268\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJennifer A. Ong, Paul W. Groundwater, and David E. Hibbs\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 268\u003c\/p\u003e \u003cp\u003e12.2 What is a Pharmacophore? 269\u003c\/p\u003e \u003cp\u003e12.3 Pharmacophore Models of Cardiovascular Drugs 270\u003c\/p\u003e \u003cp\u003e12.4 Pharmacophore Models for Anticancer Drugs 285\u003c\/p\u003e \u003cp\u003e12.5 Pharmacophore Models for Anti‐Inflammatory Drugs 290\u003c\/p\u003e \u003cp\u003e12.6 Pharmacophore Models for Anti‐Infective Drugs 297\u003c\/p\u003e \u003cp\u003e12.7 Pharmacophore Models for Neurological Drugs 299\u003c\/p\u003e \u003cp\u003e12.8 Pharmacophore Models for Miscellaneous Drugs 305\u003c\/p\u003e \u003cp\u003e12.9 Conclusions 309\u003c\/p\u003e \u003cp\u003eReferences 309\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Use of Kava as a Phytotherapeutic Agent and Kava‐Related Hepatotoxicity 312\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDong Fu and Iqbal Ramzan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 312\u003c\/p\u003e \u003cp\u003e13.2 Active Components in Kava 313\u003c\/p\u003e \u003cp\u003e13.3 Therapeutic Applications of Kava 314\u003c\/p\u003e \u003cp\u003e13.4 Pharmacology of Kava 314\u003c\/p\u003e \u003cp\u003e13.5 Side Effects of Kava 317\u003c\/p\u003e \u003cp\u003e13.6 Hepatotoxicity of Kava 318\u003c\/p\u003e \u003cp\u003e13.7 Summary and Future Challenges 322\u003c\/p\u003e \u003cp\u003eReferences 323\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Phytotherapies as New Drug Sources: Gossypol and Curcumin 330\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eVivian Wan Yu Liao, Rajeshwar Narlawar, David E. Hibbs, and Paul W. Groundwater\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Botanical Sources of Gossypol and Curcumin 330\u003c\/p\u003e \u003cp\u003e14.2 Stereoisomerism, Tautomerism, and Reactivity 332\u003c\/p\u003e \u003cp\u003e14.3 Biological Activity of Gossypol and its Analogues 337\u003c\/p\u003e \u003cp\u003e14.4 Biological Activity of Curcumin and its Analogues 346\u003c\/p\u003e \u003cp\u003eReferences 360\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Phytotherapies for the Management of Obesity and Diabetes 370\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMichel Rapinski and Alain Cuerrier\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 370\u003c\/p\u003e \u003cp\u003e15.2 Plants from the North American Pharmacopoeia 372\u003c\/p\u003e \u003cp\u003e15.3 Pharmacological Screening: Providing Empirical Evidence for Phytotherapies 379\u003c\/p\u003e \u003cp\u003e15.4 Community‐Based Participation: Developing Phytotherapies from Traditional Knowledge 385\u003c\/p\u003e \u003cp\u003e15.5 Conclusions 387\u003c\/p\u003e \u003cp\u003eReferences 387\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Phytotherapeutics for Cancer Therapy 394\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDaniel M.‐Y. Sze, Hao Liu, Maureen V. Boost, Raimond Wong, and Stephen Sagar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 394\u003c\/p\u003e \u003cp\u003e16.2 Anticancer Phytotherapeutics With NK Enhancement 395\u003c\/p\u003e \u003cp\u003e16.3 Conclusions 423\u003c\/p\u003e \u003cp\u003eReferences 425\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Phytomedicines for Fatty Liver Disease and Functional Gastrointestinal Conditions 429\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eGeorge Q. Li, Moon‐Sun Kim, Fangming Jin, and Jun‐Lae Cho\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 429\u003c\/p\u003e \u003cp\u003e17.2 Phytomedicines for FLD 430\u003c\/p\u003e \u003cp\u003e17.3 Phytomedicines for IBS 439\u003c\/p\u003e \u003cp\u003e17.4 Phytomedicines for Constipation 444\u003c\/p\u003e \u003cp\u003e17.5 Summary and Future Perspectives 448\u003c\/p\u003e \u003cp\u003eReferences 448\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Phytomedicines for Inflammatory Conditions 464\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSigrun Chrubasik‐Hausmann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Traditional Medicines for Inflammatory Conditions in Europe 464\u003c\/p\u003e \u003cp\u003e18.2 Twenty‐First‐Century Update on Paids 465\u003c\/p\u003e \u003cp\u003e18.3 Oral Extracts from \u003ci\u003eSalix \u003c\/i\u003eSpecies 465\u003c\/p\u003e \u003cp\u003e18.4 Oral Extracts from \u003ci\u003eHarpagophytum procumbens \u003c\/i\u003e468\u003c\/p\u003e \u003cp\u003e18.5 Oral Avocado–Soybean Unsaponifiables 469\u003c\/p\u003e \u003cp\u003e18.6 Oral Extracts From \u003ci\u003eTripterygium wilfordii \u003c\/i\u003e473\u003c\/p\u003e \u003cp\u003e18.7 Oral Paids Containing Unsaturated Fatty Acids 475\u003c\/p\u003e \u003cp\u003e18.8 Other Oral Paids 476\u003c\/p\u003e \u003cp\u003e18.9 Topical Paids 477\u003c\/p\u003e \u003cp\u003eReferences 478\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Phytotherapies for Infectious Diseases: Are These Really Useful? 483\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eGail B. Mahady, Gabrielle Escalante, Pooja Mikkilineni, Laura J. Mahady, Temitope O. Lawal, and Bolanle A. Adeniyi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eThe History of Medicine 483\u003c\/p\u003e \u003cp\u003e19.1 Introduction 484\u003c\/p\u003e \u003cp\u003e19.2 Historical Precedent for Natural Products as Antimicrobial Drugs 486\u003c\/p\u003e \u003cp\u003e19.3 Are Phytotherapies Useful for the Treatment of Infectious Diseases? 487\u003c\/p\u003e \u003cp\u003e19.4 Naturally Occurring Compounds that may Reduce Zoonosis 495\u003c\/p\u003e \u003cp\u003e19.5 Synergistic and Additive Effects with Antibiotics 496\u003c\/p\u003e \u003cp\u003e19.6 New Emerging Infectious Diseases and those with no Known Treatments 496\u003c\/p\u003e \u003cp\u003e19.7 SARS 497\u003c\/p\u003e \u003cp\u003e19.8 Reducing MRSA Carriage 498\u003c\/p\u003e \u003cp\u003e19.9 Conclusions 499\u003c\/p\u003e \u003cp\u003eReferences 500\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Phytomedicines for CNS Disorders: Safety Issues for use with Antiepileptic Drugs 504\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSophia Yui Kau Fong, Rosina Yau Mok, Qiong Gao, Yin Cheong Wong, and Zhong Zuo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20.1 Introduction 504\u003c\/p\u003e \u003cp\u003e20.2 Methodology of Systematic Literature Search 506\u003c\/p\u003e \u003cp\u003e20.3 Pharmacokinetic Interactions 506\u003c\/p\u003e \u003cp\u003e20.4 Pharmacodynamic Interactions 512\u003c\/p\u003e \u003cp\u003e20.5 Conclusions 524\u003c\/p\u003e \u003cp\u003eReferences 524\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Phytotherapies: Drug Interactions in Cancer 536\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAndrew J. McLachlan and Stephen J. Clarke\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21.1 Introduction 536\u003c\/p\u003e \u003cp\u003e21.2 Use of Herbal and Complementary Medicines by People Living with Cancer 537\u003c\/p\u003e \u003cp\u003e21.3 Mechanisms of Phytotherapy–Drug Interactions 538\u003c\/p\u003e \u003cp\u003e21.4 Selected Examples of Phytotherapy Medicines that have the Potential to Cause Drug Interactions in Cancer 540\u003c\/p\u003e \u003cp\u003e21.5 Future Perspectives: Need for Evidence and Advice to Cancer Patients and Physicians 546\u003c\/p\u003e \u003cp\u003e21.6 Conclusions 547\u003c\/p\u003e \u003cp\u003eAcknowledgments 547\u003c\/p\u003e \u003cp\u003eConflict of Interest 547\u003c\/p\u003e \u003cp\u003eReferences 547\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Quality Use of Medicines: Considerations in Phytotherapy 554\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLynn Weekes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22.1 Introduction 554\u003c\/p\u003e \u003cp\u003e22.2 Relevance of Qum for Herbal Medicines 556\u003c\/p\u003e \u003cp\u003e22.3 Use of Phytotherapies by Consumers 558\u003c\/p\u003e \u003cp\u003e22.4 Consumer Attitudes and Beliefs about Herbal Medicines 559\u003c\/p\u003e \u003cp\u003e22.5 Applying the Qum Framework to Phytotherapies 561\u003c\/p\u003e \u003cp\u003e22.6 Building Blocks for Quality Use of Herbal Medicines 566\u003c\/p\u003e \u003cp\u003e22.7 Conclusion 570\u003c\/p\u003e \u003cp\u003eReferences 570\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23 Intellectual Property and Patent Issues with Phytotherapy Products 573\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eGint Silins, Jennifer Tan, and Kelvin Chan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23.1 Introduction 573\u003c\/p\u003e \u003cp\u003e23.2 IP Rights—Phyto‐Industry 575\u003c\/p\u003e \u003cp\u003e23.3 Brief Overview of Patents and the Patenting Process 578\u003c\/p\u003e \u003cp\u003e23.4 Other Types of IP Rights 585\u003c\/p\u003e \u003cp\u003e23.5 Patenting Trends for Phytotherapeutics 587\u003c\/p\u003e \u003cp\u003e23.6 Traditional Knowledge and IP Rights 587\u003c\/p\u003e \u003cp\u003eDisclaimer 589\u003c\/p\u003e \u003cp\u003eReferences 590\u003c\/p\u003e \u003cp\u003e\u003cb\u003e24 International Regulatory Status of Phytotherapies 593\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eErnest V. Linek\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24.1 Introduction 593\u003c\/p\u003e \u003cp\u003e24.2 Specific Country Regulations 596\u003c\/p\u003e \u003cp\u003e24.3 Future of Phytotherapies: World Health Organization (WHO) 631\u003c\/p\u003e \u003cp\u003eFurther Reading 634\u003c\/p\u003e \u003cp\u003eIndex 635\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Chemistry [\u003ca title=\"See our other books on Chemistry\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Chemistry%20%5BPN%5D%22\"\u003ePN\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley","offers":[{"title":"Brand New","offer_id":52417762689304,"sku":"9781118268063","price":148.45,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9781118268063.jpg?v=1784507354","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/phytotherapies-efficacy-safety-and-regulation-hardback-9781118268063","provider":"Freshly Printed Books","version":"1.0","type":"link"}